RESUMEN
OBJECTIVE To systematically evaluate the efficacy and safety of fondaparinux versus low molecular weight heparin（nadroparin，enoxaparin）in the treatment of non-ST-elevation acute coronary syndrome （NSTE-ACS）. METHODS The computer searched PubMed ，Medline，Embase，EBSCO，CNKI，Wanfang medical network ，VIP Chinese Journal Full-text Database and relevant clinical trial registration network for the clinical retrospective cohort study （RCS）of fondaparinux （as trial group）and low molecular weight heparin （natroparin，enoxaparin）（as control group ）in the treatment of NSTE-ACS. The retrieval time limit was from the establishment of the database to August 2021. Newcastle Ottawa scale （NOS）was used to evaluate the quality of literature. Outcome indicators included primary efficacy indicators （incidence of acute myocardial infarction and recurrent angina pectoris during hospitalization ），secondary efficacy indicators [revascularization of target vessels during 话：0835-2862024。E-mail：xiexingxing07@163.com hospitalization， prothrombin time （PT）， activated partial thromboplastin time （APTT）]，safety indicators （incidence of serious cardiovascular events ，severe bleeding ，slight bleeding and severe puncture site co mplications during hospitalization ），combined endpoint indicators （30 and 180 days combined endpoint）. RevMan 5.3 software was used for Meta-analysis of each effect index. RESULTS Finally，17 RCS articles were included，involving 4 946 patients with NSTE-ACS ，including 2 507 in the trial group and 2 439 in the control group.The results of NOS literature quality evaluation showed that there were 8 high-quality studies ，accounting for 47.06％ . The results of Meta-analysis showed that there was no significant difference in the incidence of acute myocardial infarction ，recurrent angina pectoris，revascularization of target vessels ，PT and serious cardiovascular events between 2 groups （P＞0.05）；there was significant difference in the APTT （MD＝1.34，95％CI of 0.22-2.45，P＜0.05），the incidence of severe bleeding （RR＝0.47， 95％CI of 0.30-0.74，P＜0.05），the incidence of slight bleeding （RR＝0.48，95％CI of 0.32-0.71，P＜0.05），the incidence of severe puncture site complications （RR＝0.48，95％CI of 0.25-0.95，P＜0.05），30 day combined endpoint （RR＝0.57，95％CI of 0.46-0.72，P＜0.05），180 days combined endpoint （RR＝0.73，95％CI of 0.54-0.98，P＜0.05）. CONCLUSIONS Fondaparinux in the treatment of NSTE-ACS in China has the same efficacy as low molecular weight heparin （nadroparin，enoxaparin），and has more obvious advantages in drug safety such as bleeding ，severe puncture site complications.
RESUMEN
RESUMEN Introducción: el síndrome metabólico incrementa el riesgo para enfermedad cardiovascular y duplica la mortalidad. Objetivo: identificar los factores pronósticos de muerte por síndrome coronario agudo en pacientes con síndrome metabólico. Método: se realizó estudio observacional analítico de cohorte en 186 pacientes con síndrome coronario agudo admitidos entre 01 febrero de 2015 y 20 de octubre de 2018. Se incluyeron variables clínicas y epidemiológicas; se evaluó la fuerza de asociación entre las variables cualitativas y el riesgo de desarrollar muerte por síndrome coronario agudo en presencia de síndrome metabólico con el Odds Ratio con intervalo de confianza al 95%. Se realizó análisis multivariado utilizando el modelo de regresión logística de Cox. Resultados: la prevalencia del síndrome metabólico fue 45,7 %, con edad media de 60,6 años; sexo femenino y grupo de edades mayor de 61 años duplicaron el riesgo de forma no significativa. Hipertrofia ventricular izquierda, insuficiencia cardiaca y fibrilación auricular incrementaron el riesgo de aparición de síndrome coronario agudo estadísticamente significativa en presencia del síndrome metabólico, p, 000. Disfunción ventricular izquierda moderada a severa [OR 5.7 IC 95 % (1,115-5,961) p, 000], clase de Killip-Kimball ≥II [OR 7,9 IC 95 % (3,10-20,15) p, 000] e infarto sin elevación del ST [OR 2,970 IC 95 % (1,174-7,518) p, 000], se relacionaron significativamente con la muerte. Conclusiones: el síndrome metabólico incrementa el riesgo de sufrir síndrome coronario agudo y muerte pero no está relacionado significativamente con la supervivencia.
ABSTRACT Introduction: metabolic syndrome increases the risk for cardiovascular disease and doubles mortality. Objective: to identify the prognostic factors of death due to acute coronary syndrome in patients with metabolic syndrome. Method: a cohort analytical observational study was conducted in 186 patients with acute coronary syndrome admitted between 01 February 2015 and 20 October 2018. Clinical and epidemiological variables were included; the strength of association between the qualitative variables and the risk of developing death due to acute coronary syndrome in the presence of metabolic syndrome with Odds Ratio with 95% confidence interval was evaluated. Multivariate analysis was performed using the Cox logistic regression model. Results: the prevalence of the metabolic syndrome was 45.7%, with a mean age of 60.6 years; Female sex and age group over 61 years doubled the risk in a non-significant way. Left ventricular hypertrophy, heart failure and atrial fibrillation increased the risk of the appearance of a statistically significant acute coronary syndrome in the presence of the metabolic syndrome, p, 000. Moderate to severe left ventricular dysfunction [OR 5.7 95% CI (1,115-5,961) p, 000], Killip-Kimball class ≥II [OR 7.9 IC 95% (3, 10-20, 15) p, 000] and infarction without ST elevation [OR 2.970 95% CI (1.174-7.518) p, 000], were significantly related to death. Conclusions: metabolic syndrome increases the risk of suffering acute coronary syndrome and death but it is not significantly related to survival.
RESUMO Introdução: a síndrome metabólica aumenta o risco de doença cardiovascular e duplica a mortalidade. Objetivo: identificar os fatores prognósticos do óbito por síndrome coronariana aguda em pacientes com síndrome metabólica. Método: estudo de coorte observacional analítico foi realizado em 186 pacientes com síndrome coronariana aguda admitidos entre 01 de fevereiro de 2015 e 20 de Outubro de 2018. Foram incluídos variáveis clínicas e epidemiológicas; a força de associação entre variáveis qualitativas e o risco de morte por síndrome coronária aguda, na presença de síndrome metabólica com probabilidades confiança Rácio intervalo de 95% foi avaliada. A análise multivariada foi realizada usando o modelo de regressão logística de Cox. Resultados: a prevalência da síndrome metabólica foi de 45,7%, com idade média de 60,6 anos; Sexo feminino e faixa etária acima de 61 anos dobraram o risco de forma não significativa. hipertrofia do ventrículo esquerdo, falha cardíaca e fibrilação atrial aumentou o risco de síndroma coronária aguda estatisticamente significativa na presença de síndroma metabólico, p, 000. Disfunção Ventricular Esquerda moderada a grave [OU 5,7 (IC 95% 1,115-5,961) p.000], Killip-Kimball ≥II [OR 7,9, IC de 95% (3,10-20,15) p.000] e enfarte sem elevação do segmento ST [OR 95% CI 2,970 (1,174-7,518) p.000], estavam significativamente relacionados com a morte. Conclusões: A síndrome metabólica aumenta o risco de síndrome coronariana aguda e morte, mas não significativamente associada com a sobrevivência.
RESUMEN
Objective To analyse the risk factors of vulnerable plaque biomarker and to construct an early warning system. Methods Ninety patients with suspected acute coronary syndrome (ACS) hospitalized during December 2012 and December 2013 were selected. The coronary artery lesions were divided into type I, II and III plaque groups by the morphology of atherosclerotic plaque. Serum SAA, PLGF, sCD40L and Npt were measured. The results of SAA, PLGF, sCD40L and Npt were compared. Logistic regression model was fitted to explore the main influencing factors of the vulnerable plaque. Results SAA, PLGF, sCD40L, and Npt were main influencing factors of the vulnerable plaques, and the ORs were 1.61, 1.88, 1.96 and 1.79 respectively. Conclusion The detection of SAA, PLGF, sCD40L and Npt biochemical markers in patients with chest pain is important for predicting the vulnerable plaque and guiding clinical treatment.
RESUMEN
ObjectiveTo evaluate the safety, and the brief-and prolongedterm therapeutic efficacy for im- plantation of biodegradable stent Excel combined with Tirofiban made in China into patients with acute coronary syndrome(ACS). MethodA total of 301 patients were divided into Excel group (n = 100), Cypher group (n =102) and bare metal stem(BMS) (n = 99). The Tirofiban used in three groups was administered intravenously during and after operation.The loading dose of Tirofiban was 10 μg/kg given within 3 min followed by a Tirofiban intravenous maintenance infusion in 0.15 μg/(kg·min) with micro pump for 48 hours. Safety and efficacy were compared among three groups after stents implantation by the observation of TIMI flow, complication of bleeding, changes of platelet count, haematoglobin and hematocrit, incidence of angina, acute and subacute thrombosis inner stent and major adverse cardiac events (MACE) (cardiac death, nonfatal myocardial infarction and target ves-sel revascularization). Follow-up information got from out-patient clinic and telephone call including incidence of angina, MACE and rehospitalization were comapared sucessively 1 month, 6 monthes and 12 monthes after dis- charge. ResultsAmong there groups,there were no significant differences in demographics,and physical and lab-oratory findings before treatment. Successful rate of implantation was 100 percent and the TIMI flow of class Ⅲ was found in all patients. There was no complication of stroke and massive hemorrhage of gastrointestinal tract, and no significant differences in complication of bleeding, platelet count, hemoglobin and hematocrit after implantation. Incidence rates of acute thrombosis were 0, 0.98 and 1.01 percent in three groups, and there was no significant difference in acute thrombosis inner stent among three groups (P >0.05). The rates of angina, sub.acute stent thrombosis, MACE and rehospitalization among three groups had no differences at 1 month and 6 monthes follow-up (P > 0.05), but significant differences were not found until 12 monthes follow-up (P < 0.05). Conclusions Drug-eluting stent Excel with biodegradable polymer combined with Tirofiban made in China implanted in patients with ACS were capable of preventing acute and later thrombosis inner stent. This procedure had favourable safety, and brief-term and proionge-term therapeutic efficacy.